Physician profile
Jonathan B Williamson
NPI 1881891703
$8,570.24
in general payments reported to CMS, 2019-2025
39 companies · $2,118 in 2025
The $2,118 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $378 · 2021: $157 · 2022: $886 · 2023: $1,856 · 2024: $1,914 · 2025: $2,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,879 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,878.56 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.04 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,437.16 | 2019-2025 | Entyvio, Gattex, Livtencity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,167.15 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,139.85 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $382.87 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $330.35 | 2019-2024 | |
| Genzyme Corporation | $317.05 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $241.58 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $211.36 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $184.70 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $143.88 | 2025 | Rezdiffra |
| Lilly USA, LLC | $141.06 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $98.12 | 2025 | Sucraid |
| Aimmune Therapeutics, INC. | $92.91 | 2025 | Zenpep |
| Ardelyx, INC. | $82.91 | 2023-2025 | Ibsrela |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $73.47 | 2022-2025 | Rebyota |
| Mallinckrodt Hospital Products INC. | $70.35 | 2022-2024 | Terlivaz |
| Allergan, INC. | $63.15 | 2019 | |
| Braintree Laboratories, INC. | $56.58 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $51.93 | 2022-2023 | |
| Merit Medical Systems INC | $48.33 | 2020 | |
| Vibrant Gastro, INC. | $36.90 | 2024 | Vibrant Starter Kit |
| Evoke Pharma, INC. | $35.23 | 2023-2025 | Gimoti |
| Shire North American Group INC | $35.09 | 2019 | |
| Boston Scientific Corporation | $30.14 | 2025 | Exalt Model D |
| Exact Sciences Corporation | $28.12 | 2025 | Cologuard Collection Kit |
| Pentax of America, INC. | $25.02 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Sandoz INC. | $24.97 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $22.05 | 2023 | |
| Amgen INC. | $22.00 | 2025 | Uplizna |
| Redhill Biopharma INC. | $19.14 | 2020 | |
| Pfizer INC. | $19.06 | 2025 | |
| Amag Pharmaceuticals, INC. | $17.04 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Dova Pharmaceuticals | $16.04 | 2019 | |
| Merck Sharp & Dohme LLC | $15.75 | 2019 | |
| Daiichi Sankyo INC. | $12.61 | 2019 | |
| Shionogi INC | $12.14 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.